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Background: Cerebral ischemia is associated with the activation of glial cells, infiltration of leukocytes and an
increase in inflammatory mediators in the ischemic brain and systemic circulation. How this inflammatory response
influences lesion size and neurological outcome remains unclear. D-JNKI1, an inhibitor of the c-Jun N-terminal
kinase pathway, is strongly neuroprotective in animal models of stroke. Intriguingly, the protection mediated by
D-JNKI1 is high even with intravenous administration at very low doses with undetectable drug levels in the brain,
pointing to a systemic mode of action, perhaps on inflammation.
Findings: We evaluated whether D-JNKI1, administered intravenously 3 h after the onset of middle cerebral artery
occlusion (MCAO), modulates secretion of the inflammatory mediators interleukin-6 and keratinocyte-derived
chemokine in the plasma and from the spleen and brain at several time points after MCAO. We found an early
release of both mediators in the systemic circulation followed by an increase in the brain and went on to show a
later systemic increase in vehicle-treated mice. Release of interleukin-6 and keratinocyte-derived chemokine from
the spleen of mice with MCAO was not significantly different from sham mice. Interestingly, the secretion of these
inflammatory mediators was not altered in the systemic circulation or brain after successful neuroprotection with
D-JNKI1.
Conclusions: We demonstrate that neuroprotection with D-JNKI1 after experimental cerebral ischemia is
independent of systemic and brain release of interleukin-6 and keratinocyte-derived chemokine. Furthermore, our
findings suggest that the early systemic release of interleukin-6 and keratinocyte-derived chemokine may not
necessarily predict an unfavorable outcome in this model.
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Introduction
An increase in cytokines and chemokines in the central
nervous system and in the systemic circulation has been
reported in experimental cerebral ischemia as well as in
patients with acute stroke [1,2]. Several studies showed
an association between inflammatory mediators and
brain damage, stroke progression and severity [3,4].
The intracellular c-Jun NH2-terminal kinase (JNK) path-
way is regulated in response to cerebral ischemia, leading
to the activation of apoptotic and inflammatory transcrip-
tion factors [5,6]. D-JNKI1 is a selective JNK inhibitor [7,8]
that protects neuronal cultures against excitotoxicity and
induces a high degree of neuroprotection in several models
of cerebral ischemia, both in vitro and in vivo [9,10]. The
protection can be achieved by intra-cerebroventricular in-
jection and also by intravenous administration at very low
doses with drug levels below detection in the brain [11,12],
suggesting a systemic mode of action such as on inflam-
mation. Indeed, others showed that D-JNKI1 displays anti-
inflammatory properties in models of hemorrhagic shock
and resuscitation [13] and endotoxin-induced uveitis [14].
We have previously shown that microglial activation after
middle cerebral artery occlusion (MCAO) is not affected
by D-JNKI1 neuroprotection in vivo while in vitro D-
JNKI1 has an obvious effect [12]. Here, we investigated the
influence of this potent neuroprotectant on inflammatory
mediators. Based on recent findings that the cytokine
interleukin-6 (IL-6) and the mouse ortholog of IL-8,
keratinocyte-derived chemokine (KC/CXCL1), displayed
the most significant changes in release following cerebral
ischemia [15] and knowing that JNK regulates their tran-
scription [16], we investigated whether part of the neuro-
protective effect of D-JNKI1 results from the modulation
of systemic and brain secretion of IL-6 and KC following
cerebral ischemia in mice.
Methods
Focal ischemia was induced in outbred male Crl:CD1/ICR
mice (25 to 35 g) using the filament method as previously
described [11,12]. All procedures were in accordance with
the Swiss Federal Law on Animal Welfare and were
approved by the Swiss Cantonal Veterinary Office. Briefly,
the left middle cerebral artery was occluded for 30 min and
the filament was withdrawn to allow reperfusion. Sham ani-
mals underwent the procedure without arterial occlusion.
Cerebral blood flow and temperature were recorded. Ran-
domly, a single dose of vehicle solution (0.85% sodium
chloride) or D-JNKI1 (0.1 mg/kg, NeoMPS, obtained from
Xigen SA, Epalinges, Switzerland) was injected intraven-
ously 3 h after ischemia onset. Mice were killed at different
time points after MCAO.
Plasma was obtained from cardiac blood samples (1/
16 v/v of 4% sodium citrate) by centrifugation (15 min at2500 rpm, 4°C). Mice were transcardially perfused with
PBS. To evaluate the cytokines released by the tissue rather
than those present intracellularly, we assayed the culture
medium of brain and spleen samples after an overnight in-
cubation [17,18]. Coronal brain slices 2 mm thick and a
segment of the spleen 5 mm thick were incubated in wells
containing 1.5 mL of DMEM medium (Dulbecco’s Modi-
fied Eagle Medium 1X, 4.5 g/L glucose, L-glutamine,
GIBCO, UK), 10% horse serum (Oxoid Ltd., Basingstoke,
UK) supplemented with 11.0 mg/mL sodium pyruvate
(100 mM, Sigma, USA) and 10 mL/L penicillin:strepto-
mycin (Sigma, USA) for 20 h at 37°C in humidified air with
5% CO2. Control mice were used to distinguish between
the release due to MCAO and that resulting from tissue
preparation and culture. The medium was centrifuged
(5 min at 12,000 rpm, room temperature). The superna-
tants were frozen at −80°C. Protein concentrations were
determined by Bradford assay.
To assess cytokine levels in brain homogenates, the slice
adjacent to the one tested for brain cytokine release was
directly frozen in liquid nitrogen and conserved at −80°C
for further analysis. Frozen sections were cut again into
20 μm slices using a cryostat and the ipsilateral and
contralateral hemispheres were separated and collected.
Slices were homogenized in buffer (20 mM tris(hydroxy-
methyl)aminomethane-acetate, pH 7.0; 0.27 M sucrose;
1 mM ethylenediaminetetraacetic acid; 1 mM ethylenegly-
coltetraacetic acid; 50 mM sodium fluoride; 10 mM beta-
glycerophosphate; 5 mM sodium pyrophosphate; 1 mM
sodium vanadate; 1% Triton X) containing protease inhibi-
tors. After centrifugation (15 min at 10,000 rpm, 4°C),
supernatants were collected and protein concentrations
calculated according to the Bradford method.
An ELISA was performed using half the quantities
recommended by the manufacturer for the detection of
mouse IL-6 (OptEIA TM Set, BD Biosciences, San Diego,
CA) and KC/CXCL1 (DuoSet ELISA Development System,
Abingdon, UK) in plasma, supernatants from incubated
brains and spleens, and supernatants from brain homoge-
nates. The optical density was measured at 450 nm.
Immunohistochemical labeling and double immunofluor-
escence of brain sections were performed according to previ-
ously published data [12] using the following antibodies:
mouse anti-Neuronal Nuclei (NeuN, 1/500, Millipore),
mouse anti-Glial Fibrillary Acidic Protein (GFAP, 1/500,
Millipore), rat anti-CD11b (Mac-1, 1/100, AbD Serotec,
UK), rabbit polyclonal anti-IL-6 antibody (1/200, ab6672,
Abcam, Cambridge, UK), anti-growth-related protein alpha
antibody against chemokine KC/CXCL1 (GRO-alpha, 1/100,
ab86436, Abcam, Cambridge, UK). Images were acquired
with the Aviovision v3.1 software using a Zeiss Axiovision
microscope.
Results were expressed as mean ± standard error of the
mean (SEM). Cytokine concentration data were square
Benakis et al. Journal of Neuroinflammation 2012, 9:76 Page 3 of 8
http://www.jneuroinflammation.com/content/9/1/76root-transformed to bring distributions closer to normal
and reduce variance inequalities before statistical analysis.
Comparisons between three or more groups were per-
formed using one- or two-way analysis of variance. For
post-hoc comparisons, a Brown-Forsythe test for equality
of variances between groups was performed, followed by
Tukey’s comparison of means when variances were equal
or a Games-Howell test when variances were unequal.
Paired statistical tests were used to compare cytokine con-
centration in the ipsilateral versus the contralateral hemi-
sphere at each time point for both the MCAO+vehicle and
the MCAO+D-JNKI1 mice (JMP 9.0.0 and IBM SPSS sta-
tistics 19.0.0). P <0.05 was considered significant.
Results
The plasma concentrations of both IL-6 and KC
increased markedly 4 h and 7 h after MCAO onset in
vehicle-treated mice (Figure 1A,B; P <0.05). From 24 h
(data not shown) to 48 h the concentrations decreased
to control levels. Interestingly, as late as 5 d after ische-
mia, the secretion of IL-6 and KC increased again
compared to shams (P= 0.054 and P <0.05, respectively).
D-JNKI1 induced a non-significant reduction in IL-6
plasma levels at 4 h and 5 d (Figure 1A) while KCFigure 1 Two peaks of interleukin-6 and keratinocyte-derived chemok
occlusion. Square root-transformed (SQRT) IL-6 and KC plasma concentrati
treated with vehicle or D-JNKI1. (A) In sham mice, IL-6 did not differ from c
after MCAO+vehicle at a significantly higher level than sham mice. At 24 h
returned to basal level and increased again 5 d after the occlusion (sham v
MCAO+D-JNKI1 mice was slightly reduced at 4 h and 5 d but not statistica
MCAO+D-JNKI1: P= 0.26; 5 d: MCAO+vehicle versus MCAO+D-JNKI1: P= 0.2
was significantly higher compared with sham mice. (B) Plasma KC was indu
decreased from 24 h (data not shown) onwards. Five days after MCAO, KC
versus MCAO+vehicle: P= 0.03). KC concentration in MCAO+D-JNKI1 mice w
between the two groups. In the sham group, KC concentrations at 4 h, 7 a
Control mice: n = 7; sham mice: n = 5 to 8, except at 24 h, n = 3; MCAO mic
between MCAO and sham mice. Results are presented as mean ± SEM. Wh
difference with concentrations in the same group at 0 h, 4 h and 7 h, respeconcentrations were not influenced by the treatment
(Figure 1B). The 24 h time point was not tested in
MCAO+D-JNKI1 mice as no significant difference was
found between sham and MCAO+vehicle (not shown).
Overall, we did not find a significant difference between
MCAO+D-JNKI1 and MCAO+vehicle at any time points
tested for either of the inflammatory mediators, despite a
significant lesion volume reduction 48 h after MCAO
with D-JNKI1 (36.4 ± 4.3 mm3 in vehicle mice, n= 7 and
19.0 ± 5.5 mm3 in D-JNKI1-treated mice, n= 5; t-test: P
<0.05). In sham mice, the systemic IL-6 release did not
differ from controls at any time point but there was a
significant increase of KC at 4 h, 7 h and 24 h. While
these findings suggest an early transient KC secretion
into the plasma of sham mice due to the anesthesia [19]
and the surgical procedure, the release of KC after
MCAO was far greater. We also investigated the secre-
tion of IL-6 and KC from the spleen at 4 h, 7 h, 48 h and
5 d in sham mice, control mice and after MCAO in mice
with and without DJNKI1. We did not find any signifi-
cant changes in either IL-6 or KC in spleen supernatants
in any of the four groups tested (Figure 2).
The release of IL-6 and KC from the brain increased
significantly at 7 h compared to early time points (0 hine release into the plasma after middle cerebral artery
ons at different time points in control mice, sham and MCAO mice
ontrol mice at any time point. Plasma IL-6 was induced 4 h and 7 h
(data not shown) and 48 h, IL-6 concentrations in MCAO+vehicle mice
ersus MCAO+vehicle: P= 0.054). The plasma IL-6 concentration in
lly different from MCAO+vehicle mice (4 h: MCAO+vehicle versus
7). Seven hours after MCAO, IL-6 concentration in D-JNKI1-treated mice
ced early in MCAO+vehicle mice compared to sham mice and
concentration was again significantly higher than in sham mice (sham
as similar to MCAO+vehicle mice, without any statistical difference
nd 24 h (data not shown) were significantly higher than in controls.
e: n = 6 to 10. *P <0.05, **P <0.01 indicate a significant difference
en placed over a data point, ∞,  and× indicate a significant .
ctively.
Figure 2 Release of interleukin-6 and keratinocyte-derived chemokine from the spleen after middle cerebral artery occlusion.
Concentrations of IL-6 and KC were measured in the supernatants of spleen slice cultures and normalized to total protein concentrations. The
graphs show the square root (SQRT) of (A) IL-6 and (B) KC concentrations in pg/mg at different time points from control (n = 7), sham (n = 4 to 8),
MCAO+vehicle (n = 6 to 10) and MCAO+D-JNKI1 (n = 5 to 8) mice. IL-6 release from the spleen increased slightly, though not significantly, at 4 h
in both MCAO+vehicle and MCAO+D-JNKI1 mice. Overall, there is no significant change in IL-6 and KC in spleen supernatants in any of the four
groups tested. Results are represented as mean ± SEM.
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MCAO (Figure 3). In comparison with shams, there was
an increase in IL-6 levels at 24 h (P= 0.06, not shown)
and 48 h (P <0.05). A slight increase was also observedFigure 3 Release of interleukin-6 and keratinocyte-derived chemokine
Concentrations of IL-6 and KC were measured in the supernatants of brain
graphs show the square root (SQRT) of IL-6 and KC concentrations in pg/m
mice, the cerebral release of IL-6 and KC did not differ from control mice a
increase at 24 h (sham versus MCAO+vehicle: P= 0.06, data not shown) wit
the occlusion. A slight, non-significant reduction of IL-6 release from the br
versus MCAO+D-JNKI1: P= 0.25). There was no significant difference of brai
MCAO+D-JNKI1 mice, IL-6 concentrations at 48 h remained significantly hi
increase significantly at 7 h compared to early time points (0 h and 4 h) an
slightly, though not significantly, at 24 h (P= 0.19, data not shown) and 48
in MCAO+D-JNKI1 mice followed the same temporal profile as in MCAO+
n= 3; MCAO mice: n = 6 to 10. *P <0.05 indicates a significant difference in
When placed over a data point, ∞ and indicate a significant difference wat 5 d, not reaching significance (P= 0.12; Figure 3A).
Brain KC release tended to increase, although not signifi-
cantly, at 24 h (P= 0.19, not shown) and 48 h (P= 0.08)
after MCAO compared to shams (Figure 3B). Thefrom the brain after middle cerebral artery occlusion.
slice cultures and normalized to total protein concentrations. The
g at different time points in control, sham and MCAO mice. In sham
t any time point. (A) Secretion of IL-6 from the brain tended to
h a significant difference between sham and MCAO+vehicle 48 h after
ain in mice treated with D-JNKI1 was seen at 5 d (MCAO+vehicle
n IL-6 release in D-JNKI1- and vehicle-treated mice at any time point. In
gher than in controls. (B) KC release in MCAO+ vehicle mice started to
d remained elevated at late time points. The brain KC release increased
h (P= 0.08) after MCAO compared with sham mice. KC concentrations
vehicle mice. Control mice: n = 7; sham mice: n = 5 to 8, except at 24 h,
MCAO mice and sham mice. Results are represented as mean± SEM.
ith concentrations in the same group at 0 h and 4 h, respectively.
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fer from controls at any time point. A slight, non-
significant reduction of brain IL-6 release was seen at 5
d with D-JNKI1 treatment. We did not find any signifi-
cant change in brain IL-6 or KC release in D-JNKI1-
treated mice at any time point, despite a significant
lesion volume reduction at 48 h. To ensure that these
results were not methodological artifacts, we also ana-
lyzed concentrations of IL-6 and KC in frozen brain sam-
ple homogenates from the same mice (Figure 4). We
found a similar increase in brain IL-6 and KC 48 h after
MCAO in both vehicle- and D-JNKI1-treated groups in
the ipsilateral hemisphere compared with the contralateral
(Figure 4), supporting our results of cytokine release from
brain tissue (Figure 3).
To investigate the cellular localization of IL-6 and KC
after MCAO, we performed immunohistochemistry in
the cortex at 48 h, when we obtained significant neuro-
protection with D-JNKI1. We found an up-regulation of
IL-6 and KC in the infarcted tissue, in both vehicle-
treated (n = 2 to 3) and D-JNKI1-treated (n = 2) mice
compared with the contralateral hemisphere (data notFigure 4 Interleukin-6 and keratinocyte-derived chemokine concentra
measured in brain homogenates and normalized to total protein concentra
concentrations in pg/mg at several time points from control, sham and MC
mice at any time points. (A) Brain IL-6 concentration in the hemisphere ips
with control mice (0 h) and with the 4 h time point. A non-significant incre
at 48 h (MCAO+vehicle: P= 0.25; MCAO+D-JNKI1: P= 0.32; plain columns). T
vehicle- and D-JNKI1-treated mice at any time points. In MCAO+D-JNKI1 m
4 h and 7 h and decreased significantly at 5 d (P= 0.02). (B) Brain KC conce
at 4 h in both groups (MCAO+vehicle: P= 0.08; MCAO+D-JNKI1: P= 0.04) an
with sham mice. KC concentrations in MCAO+D-JNKI1 mice at 48 h remain
at 5 d (P= 0.006). Matched pairs analysis between the ipsilesional (ipsi, plain
showed that there is an increase in (A) brain IL-6 at 7 h and 48 h after MCA
and until 48 h in both MCAO groups compared with the contralesional hem
n= 3 to 7; MCAO+D-JNKI1: n = 7 to 8. *P <0.05 and **P <0.02 indicates a
mean ± SEM. When placed over a data point, ∞,  and× indicate a signific
7 h, respectively.shown) or to sham mice. Even though IL-6 and KC
staining looks faint in the D-JNKI-treated mice, the la-
beling pattern and cellular localization were comparable
between the two groups (Figure 5A). We performed
double immunofluorescence using antibodies against IL-
6, KC and NeuN, GFAP, CD11b to label neurons, astro-
cytes or microglial cells (peripheral macrophages and
resident microglia), respectively. In MCAO-vehicle mice,
IL-6 was found in neurons and microglia but not astro-
cytes, as previously described [20]. D-JNKI1-treated mice
showed similar IL-6 labeling with slightly more ramified
microglia [12] (Figure 5B). In both D-JNKI1- and
vehicle-treated mice, KC was found predominantly in
astrocytes and microglia, as previously described [21].
Neuronal KC labeling was non-nuclear. Overall, there
was no difference in KC labeling between groups
(Figure 5C).
In agreement with previously publications, we found
an increase in IL-6 and KC in the blood of MCAO mice
that precedes the release from the brain [15,22,23]. IL-6
and KC secretion from the spleen was not affected by
MCAO. Furthermore, we showed, for the first time, ations in brain homogenates. Concentrations of IL-6 and KC were
tions. The graphs show the square root (SQRT) of IL-6 and KC
AO mice. In sham mice, brain IL-6 and KC did not differ from control
ilateral to the lesion in MCAO+vehicle mice increased at 7 h compared
ase of brain IL-6 in MCAO+vehicle and MCAO+D-JNKI1 mice was seen
here was no significant difference in brain IL-6 release between
ice, IL-6 concentrations at 48 h remained significantly higher than at
ntration in the ipsilateral hemisphere of MCAO mice increased slightly
d at 48 h (MCAO+vehicle: P= 0.27; MCAO+D-JNKI1: P= 0.17) compared
ed significantly higher than control mice and decreased significantly
columns) and contralesional (contra, dashed columns) hemispheres
O in both groups and that (B) brain KC has already increased by 4 h
isphere. Control mice: n = 3; sham mice: n = 3 to 5; MCAO+ vehicle:
significant difference. N.S.: not significant. Results are represented as
ant difference with concentrations in the same group at 0 h, 4 h and
Figure 5 Localization of interleukin-6 and keratinocyte-derived chemokine in the brain 48 h after middle cerebral artery occlusion.
Coronal brain sections were immunolabeled with specific antibodies 48 h after MCAO. (A) Representative IL-6 and KC immunohistochemistry of
the ischemic cerebral cortex of vehicle- and D-JNKI1-treated animals (left panels). Both cytokines are up-regulated in the ischemic region
compared with sham mice, which show little labeling (right panels). Nissl-stained coronal sections are shown at the top. The paler area is the
ischemic lesion. (B, C) Double immunofluorescent staining of neurons (NeuN; red, top line), astrocytes (GFAP; red, middle line) or microglia
(CD11b; red, bottom line), and IL-6 (green, left panel) or KC (green, right panel) in the ischemic cortex of vehicle- and D-JNKI1-treated mice.
Yellow staining shows co-localization of IL-6 (B) with neurons and microglia but not astrocytes. KC (C) co-localizes mainly with astrocytes and
microglia rather than neurons. D-JNKI1 treatment does not obviously change IL-6 and KC cell localization after MCAO.
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http://www.jneuroinflammation.com/content/9/1/76second, later systemic increase in these inflammatory
mediators using two methods. The cellular location of
IL-6 and KC in the brain was similar in both groups
48 h after ischemia. Importantly, our results show that
neuroprotection mediated by D-JNKI1 after cerebral is-
chemia is independent of the early systemic release of
IL-6 and KC, and reveal a later secretion from the brain.
Discussion
After a stroke, cytokines and chemokines may play a patho-
genic part in the lesion development, passively reflect the is-
chemic brain injury or have other physiological roles
[2,20,24]. The increased production of IL-6 in patients with
large strokes could be the result and/or the cause of the
enlarged cerebral infarctions [20,25]. We hypothesized that
the intravenous administration of neuroprotective agent D-
JNKI1 may have anti-inflammatory properties that attenuate
the lesion size. On the contrary, we demonstrated that the
early systemic release of IL-6 and KC and later increase in
the brain are not significantly reduced by D-JNKI1 treat-
ment. Others have published that the related JNK inhibitor,
L-JNKI1, did not reduce brain cytokine or chemokine
mRNA expression 3 h after perinatal hypoxia–ischemia des-
pite neuroprotection [26].
The results show that brain KC and IL-6 production, al-
though regulated by JNK [16], is not affected by these JNK
inhibitors after cerebral ischemia and suggest that neuro-
protection through JNK inhibition occurs independently
of IL-6 and KC in this model and at the time points inves-
tigated. Others showed that D-JNKI1 significantly pre-
vented liver injury after hemorrhage and resuscitation by
inhibiting cytokine production [13], which is also true in a
model of uveitis [14]. This suggests that D-JNKI1 could
have distinct anti-inflammatory effects depending on the
disease, its severity, the time and route of administration
and administered dose.
In our MCAO model, the early systemic increase in IL-6
and KC is linked to the cerebral arterial occlusion but may
not necessarily predict an unfavorable outcome. It is pos-
sible, however, that these inflammatory mediators contrib-
ute to the damage observed in DJNKI1-treated mice. The
source of the systemic cytokines remains to be defined. We
found no significant change in splenic secretion, in contrast
with severe ischemia [23], suggesting that moderate ische-
mia induces less systemic inflammation. In the ischemic
brain at 48 h, neurons and microglia were the major source
of IL-6 while KC originated mostly from glial cells, with and
without D-JNKI1 treatment. Furthermore, our results sug-
gest that the second systemic increase in inflammatory
mediators in mice with MCAO reflects ongoing tissue dam-
age, possibly influencing the outcome at later time points.
Although the overall survival of the mice in these experi-
ments was not significantly different between groups (data
not shown), no death was recorded beyond 24 h afterischemia in the D-JNKI1-treated group. D-JNKI1 may
therefore have a delayed beneficial physiopathological effect
after MCAO, explaining the slight systemic decrease in IL-
6 and KC at 5 d in D-JNKI1-treated mice (Figures 3 and 4)
but this will require further investigation.
In summary, we demonstrate that neuroprotection
with D-JNKI1 does not significantly reduce brain and
early systemic secretion of IL-6 and KC after moderate
ischemia and that the spleen is not the major source of
the early systemic secretion. Taken together with our
earlier studies [12], these results show that neuroprotec-
tion by JNK inhibition occurs independently of micro-
glial activation and IL-6 and KC secretion, an important
observation in a widely used stroke model with striking
neuroprotection. Brain-immune system interactions are
complex in experimental ischemia models and detailed
characterizations of the differential effects of the model
on observed immune system effects are important.
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